Consumption and pharmaceutical expenditure |
Italian Medicines Agency
Aifa toggle bar Search
Search keywords
The Agency
The Agency
Mission and values
Organisation
Scientific and Economic Committee for Medicines
Support and Coordination Secretariats and Advisory Committees
International Collaborations
EU Projects
Legislation
Forms
Competition notices
Resolutions
Tenders and contracts
Quality assurance
Guarantee Committee
Atti di notifica
Associazioni dei pazienti
AIFA Incontra
Contacts
Certified email
COVID-19
COVID-19
Communications about COVID-19
COVID-19 Vaccines
Medicines usable for treatment of COVID-19 disease
Use of monoclonal antibodies for COVID-19
Use of antivirals for COVID-19
Monitoring of medicinal products used during the COVID-19 epidemic
Clinical Trials - COVID-19
Compassionate Use Programs - COVID-19
Access to medicinal products
Access to medicinal products
Early access and off-label use
Authorisation of medicinal products
Medicine shortages
Antibiotic medicinal products
Biological medicinal products
Vaccines
Blood derivatives
Generic medicinal products
Biosimilar medicinal products
Orphan medicinal products
Advanced therapies
Homeopathic medicinal products
Allergens
Medicinali di origine vegetale
Ancillary medicinal substances incorporated in medical devices
Safety of medicinal products
Safety of medicinal products
Pharmacovigilance
National Pharmacovigilance Network
Adverse Reactions to medicinal products
Persons in charge of Pharmacovigilance
European Eudravigilance System
Accesso alle segnalazioni - ADRreports
Regional pharmacovigilance funds
Segnali di sicurezza
Risk management measures
Medicinal products subject to additional monitoring
Quality and Inspections
Quality and Inspections
Quality defects
Inspections and authorisations
Qualified person
Fight of pharmaceutical crime
Research and Clinical trials
Research and Clinical trials
Clinical trials concerning medicinal products
EU Regulation on Clinical trials
National Observatory on Clinical Trials
Registro Studi Osservazionali
Comitati Etici Nazionali (CEN)
Ethics Committees Coordination Centre
Independent clinical research
Mappa dei centri di Sperimentazione Clinica
Pricing and reimbursement
Pricing and reimbursement
Negotiation and reimbursement
Economic evaluations
Monitoring Registers
AIFA Notes
Lists of Class A and Class H medicinal products
Innovative medicinal products
Transparency Lists
Consumption and pharmaceutical expenditure
Consumption and pharmaceutical expenditure
The Medicines Utilization Monitoring Centre (OsMed)
Governance of pharmaceutical expenditure
Monitoring pharmaceutical expenditure
Innovation and planning
Innovation and planning
Innovation and scientific advice
Horizon scanning
Information and communication
Information and communication
FarmaciLine
Medical and scientific information
FAQ
Publications
Communication campaigns
Eventi AIFA
Scientific Seminars
Press releases
Dossier AIFA
Mobile APP AIFA
APP Firstline AIFA - Antibiotici
ABC della Ricerca Clinica
Presentations and speeches
Public consultations and documents
Documents shared with scientific communities
Calendario eventi
Archivio
AIFA data
AIFA data
OsMed Data
Open Data
Companies Section
Companies Section
Requests for authorisation of conferences and meetings
Payment of fees and annual duties
MA Electronic invoicing
Application for reimbursement and pricing
Access information
Notifica concessionari di vendita
Comunicazione prima commercializzazione
Open governance
Open governance
Disposizioni Generali
Organizzazione
Consulenti e collaboratori
Personale
Bandi di Concorso
Performance
Enti controllati
Attività e procedimenti
Provvedimenti
Bandi di gara e contratti
Sovvenzioni, contributi, sussidi, vantaggi economici
Bilanci
Beni immobili e gestione patrimonio
Controlli e rilievi sull'Amministrazione
Servizi Erogati
Pagamenti dell'Amministrazione
Opere pubbliche
Pianificazione e governo del territorio
Informazioni ambientali
Interventi straordinari di emergenza
Altri Contenuti
Consumption and pharmaceutical expenditure
Consumption and pharmaceutical expenditure
The analysis of consumption and of outpatient and inpatient NHS pharmaceutical expenditure is a necessary tool for planning health policy interventions. Periodic monitoring of drug consumption and expenditure makes it possible to promptly identify emerging phenomena, frame prescriptive behaviours and verify the effectiveness of regulatory measures at national and regional level.
When the NHS pharmaceutical spending ceiling is exceeded, the Agency shall take action by launching the payback procedures.
List of news
21/04/2026
Medicine Use: 2024 Regional Reports Now Available Online
27/03/2026
Biosimilars: AIFA webinar on the Third Position Paper
16/03/2026
Verifica dei dati trasmessi alla banca dati per la tracciabilità del farmaco e aggiornamento dei dati ai fini del procedimento di ripiano, per l'anno 2025
05/03/2026
Programmazione della spesa farmaceutica: incontro AIFA-Regione Siciliana
18/02/2026
Biosimilar medicines in Italy: AIFA reports updated
29/01/2026
Monitoring of Pharmaceutical expenditure - January / September 2025
08/01/2026
Applicazione della riduzione del 5% - aggiornamento dei prezzi al pubblico
31/12/2025
Legge di Bilancio 2026: abolita la facoltà di sospendere la riduzione di legge del 5%
22/12/2025
Biosimilar medicines in Italy: AIFA reports updated
19/12/2025
Interactive OsMed Now Available - Updated with the Latest Data on Medicine Consumption and Expenditure in Italy
16/12/2025
Monitoring of Pharmaceutical expenditure - January / June 2025
16/12/2025
Avvio del procedimento di Pay-Back convenzionata 1,83% e della procedura di retrocessione - 1° semestre 2025
28/11/2025
“Procedura pay-back 5% - Anno 2025” - Determina AIFA n. 80/2025 del 24 novembre 2025
25/11/2025
Biosimilar medicines in Italy: AIFA reports updated
25/11/2025
Payback convenzionata 1,83%: Procedura di revisione dell’anagrafica dei medicinali movimentati nel corso del I semestre 2025
20/11/2025
Ripiano della spesa farmaceutica per acquisti diretti per l’anno 2024
30/10/2025
Avvio procedimento e apertura piattaforma Pay-Back 5% - anno 2025
29/10/2025
Monitoring of Pharmaceutical expenditure - January / May 2025
14/10/2025
Avvio procedura di revisione dell’elenco dei medicinali nell’ambito del procedimento di Payback 5% per l’anno 2025
30/09/2025
Biosimilar medicines in Italy: AIFA reports updated
13/08/2025
Avviso di ripristino di tutte le funzionalità della piattaforma Spending-PHA
06/08/2025
Avviso di sospensione temporanea di alcune funzionalità della piattaforma Spending-PHA
01/08/2025
Biosimilar medicines in Italy: AIFA reports updated
30/07/2025
Ripiano della spesa farmaceutica per acquisti diretti per l’anno 2024 - Avvio del procedimento - Esposizione dati
30/07/2025
Monitoring of Pharmaceutical expenditure - January / December 2024 (Final balance)
09/07/2025
Biosimilar medicines in Italy: AIFA reports updated
13/05/2025
Avvio del procedimento di Pay-Back convenzionata 1,83% e della procedura di retrocessione - 2° semestre 2024
30/04/2025
Biosimilar medicines in Italy: AIFA reports updated
30/04/2025
Monitoring of Pharmaceutical expenditure (January / December 2024)
18/04/2025
Procedure for the review and validation of lists of therapeutic indications for innovative medicines by pharmaceutical companies
16/04/2025
Payback convenzionata 1,83%: Procedura di revisione dell’anagrafica dei medicinali movimentati nel corso del II semestre dell’anno 2024
16/04/2025
“Spending-Pha”: nuovo servizio online AIFA per la gestione del procedimento di payback 1,83%
07/04/2025
Biosimilar medicines in Italy: AIFA reports updated
04/04/2025
Monitoring of Pharmaceutical expenditure (January / November 2024)
04/04/2025
Ripiano dello sfondamento del tetto della spesa farmaceutica per gli acquisti diretti per l'anno 2023 - Aggiornamento pagamenti
27/02/2025
AIFA publishes Regional Reports on the use of medicines for 2023
21/02/2025
Biosimilar medicines in Italy: AIFA reports updated
13/02/2025
Ripiano della spesa farmaceutica per acquisti diretti per l’anno 2023
13/02/2025
Monitoring of Pharmaceutical expenditure (January / October 2024)
12/02/2025
Biosimilar medicines in Italy: AIFA reports updated
10/02/2025
Verifica dei dati trasmessi alla banca dati per la tracciabilità del farmaco relativi all’anno 2024
04/02/2025
Monitoring of Pharmaceutical expenditure - January / September 2024
16/12/2024
Ripiano della spesa farmaceutica per acquisti diretti per l’anno 2023
29/11/2024
Biosimilar medicines in Italy: AIFA reports updated
29/11/2024
Avvio del procedimento di Pay-Back convenzionata 1,83% e della procedura di retrocessione - 1° semestre 2024
25/11/2024
Monitoraggio della spesa farmaceutica (gennaio - giugno 2024)
05/11/2024
Biosimilar medicines in Italy: AIFA reports updated
24/10/2024
Monitoring of Pharmaceutical expenditure - January / April 2024
11/10/2024
Avvio procedimento e apertura piattaforma Pay-Back 5% - anno 2024
27/09/2024
Biosimilar medicines in Italy: AIFA reports updated
13/09/2024
Monitoring of Pharmaceutical expenditure - January / February 2024
02/08/2024
Ripiano della spesa farmaceutica per acquisti diretti per l’anno 2023 - Avvio del procedimento - Esposizione dati
22/07/2024
Monitoring of Pharmaceutical expenditure - January / December 2023 (Final balance)
08/07/2024
Monitoring of Pharmaceutical expenditure (January / December 2023)
08/07/2024
Avvio del procedimento di Pay-Back convenzionata 1.83% - 2° semestre 2023
08/05/2024
Biosimilar medicines in Italy: AIFA reports updated
24/04/2024
Monitoring of Pharmaceutical expenditure (January / November 2023)
22/04/2024
Procedure for the review and validation of lists of medicines whose property has been transferred from a pharmaceutical company to another
22/04/2024
Procedure for the review and validation of lists of therapeutic indications for innovative medicines by pharmaceutical companies
15/03/2024
Biosimilar medicines in Italy: AIFA reports updated
All news
Consumption and pharmaceutical expenditure
The Medicines Utilization Monitoring Centre (OsMed)
Governance of pharmaceutical expenditure
Monitoring pharmaceutical expenditure
Share
Nested Applications
Highlights
21/04/2026 - Medicine Use: 2024 Regional Reports Now Available Online
17/04/2026 - From one-size-fits-all treatments to personalised care: the revolution in precision medicine
TUTTE LE NEWS - IN EVIDENZA
ALL NEWS
News
21/04/2026
Medicine Use: 2024 Regional Reports Now Available Online
15/04/2026
AIFA updates the Transparency Lists
13/04/2026
Medicine Shortage Communication on Endoxan (ciclofosfamide)
All news
Nested Applications
Press
From one-size-fits-all treatments to personalised care: the revolution in precision medicine
All press releases
Last tweets
📢 #AIFA comunica il calendario degli incontri nell’ambito delle iniziative dedicate al dialogo e al...
Vai al post →
🔬 AIFA pubblica il dossier “Dalle terapie a taglia unica alle cure su misura: la rivoluzione della ...
Vai al post →
🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m...
Vai al post →
💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ...
Vai al post →
⚠️ Attenzione alle false cure miracolose
Negli ultimi tempi si sta diffondendo un business pericol...
Vai al post →
#AIFA promuove l’ascolto e la trasparenza
Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr...
Vai al post →
Go to Twitter profile
Go to Twitter profile
aifa_ufficiale
Multimedia
Medicina di precisione e appropriatezza prescrittiva
Go to YouTube channel
Cookie Bar
Footer
The agency
Home Page
FarmaciLine
User participation and satisfaction
Citizens' access
Modulistica
Open governance
Acts of notification
Legal notification
TrovaNormeFarmaco
Competition notices
Tenders and contracts
Contacts
Via del Tritone, 181 00187 Roma
Contacts
Certified e-mail (PEC) contacts
VAT number: 08703841000
Tax code: 97345810580
IPA AIFA code: aifa_rm
IPA UCB code: UFE1TR
FOLLOW US ON
label.button.spotify
Bluesky
FEED RSS
Feed Rss
Cookie management
Sezione Link Utili
Legal notice
Social Media Policy
Dichiarazione di accessibilità
Web accessibility
Website statistics
Online services
go to beginning of content